Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum.

Abstract

The paper is aimed at evaluation of the efficacy and safety of one-year therapy with slow-release nicotinic acid (NA-SR). The study involved a group of 30 patients with hyperlipidemia of type II. The concentration of nicotinic acid in serum was determined using capillary electrophoresis. After the placebo period (2 months), NA-SR was applied at the dose of 1.5 g/d (2 months), and subsequently 2-3 g/d (10 months), on average 2.13 g/d. During the treatment with 2.0 g/d dose, the steady-state concentration of NA in serum was within a range of 2.7-4.9 microg/ml and with 3.0 g/d of 6.17-7.75 microg/ml. These doses of the drug were tolerated well and advantageously modified the serum lipids.

• Authors: J Chojnowska-Jezierska, H Adamska-Dyniewska
• Journal: International journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther) Vol. 36 Issue 6 Pg. 326-32 (Jun 1998) ISSN: 0946-1965 [Print] Germany
• PMID: 9660040 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Biomarkers
• Delayed-Action Preparations
• Niacin
• Aspartate Aminotransferases
• Alanine Transaminase
• Alkaline Phosphatase

Topics

• Adult
• Alanine Transaminase (blood)
• Alkaline Phosphatase (blood)
• Aspartate Aminotransferases (blood)
• Biomarkers (blood)
• Delayed-Action Preparations
• Flushing (chemically induced)
• Humans
• Hyperlipidemias (drug therapy)
• Male
• Middle Aged
• Nausea (chemically induced)
• Niacin (adverse effects, blood, therapeutic use)
• Stomach Diseases (chemically induced)
• Time Factors
• Treatment Outcome